Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Biovail Acquisition: UBS Approves, Paradigm Calls It 'A Little Expensive'
- FP Trading Desk submits: Biovail Corp. BVF struck a $200-million deal Monday to acquire worldwide rights for Tetrabenzene products, which treat Huntington's disease, and analysts consider it to be a logical move for the Toronto-based drugmaker. After all, Biovail already owned the marketing rights in Canada and the United...
- External links 2009-05-19
- Healthcare Sector Likely Next U.S. Market Leader
- FP Trading Desk submits: Investors in the U.S. market should watch out for a correction in the financial and retail sectors while the health care segment is set to become the next market leader, a new BCA note on American equity strategy suggests. "While the financials' comebck is impressive,...
- External links 2009-05-14
- Cardiome May See More Upside When IV Formulation Is Clarified - RBC
- FP Trading Desk submits: Cardiome Pharma Corp. CRME shares were still on the rise Monday following last week's announcement of a significant licensing agreement with Merck & Co Inc. MRK. But according to RBC Capital Markets analyst Douglas Miehm, the response from shareholders may turn even more positive once...
- External links 2009-04-14
- Biovail 'Still Not Getting the Attention It Deserves' - UBS
- FP Trading Desk submits: Biovail Corp.'s BVF latest rights acquisition is right on strategy, but whether it proves profitable will likely remain unknown for some time to come, says UBS analyst Marc Goodman. On Monday, Biovail entered into an agreement with Acadia Pharmaceuticals Inc. ACAD, to co-develop Acadia's experimental...
- External links 2009-05-05
- Johnson & Johnson: Offering Strong Yield and Steady Growth
- FP Trading Desk submits: The dash for trash in the U.S stock market may continue, but there is no replacing the safety of blue chip dividends. Johnson & Johnson JNJ sports a 3.4% dividend yield based on its current share price-higher than the yield on 10-year Treasuries. The company...
- External links 2009-05-13
- SXC Health Solutions: Strong Q1 Results Have Analysts Buzzing
- FP Trading Desk submits: Recent aggressive acquisitions and strong Q1 2009 results have industry analysts hot on rising Illinois software developer SXC Health Solutions SXCI."SXC is performing better than we expected, in part due to significant acquisition synergies being realized quickly," Macquarie analyst Glenn Jamieson wrote in a note...
- External links 2009-05-10
- Labopharm's Drug Launch Boosts Shares
- FP Trading Desk submits: Labopharm Inc. DDSS shares shot up 7% in early trading Thursday morning, after the company announced the U.S. launch of Ryzolt, its once-daily formulation of painkiller tramadol. The drug is being marketed and distributed by Purdue Pharma Products L.P. and is available in more than...
- External links 2009-05-08
- Biovail: Drug Ruling Not Expected to Have Significant Impact - RBC
- FP Trading Desk submits: A recent U.S. district court ruling that allows a rival pharmaceutical company to produce its own version of a generic painkiller will cut into the market share of Biovail Corp. BVF, but RBC Capital Markets does not expect a significant impact on the Canadian drug...
- External links 2009-08-19
- Latest Patheon Bid: Not Enough Upside for Largest Shareholder
- FP Trading Desk submits: Lonza Group AG's offer to acquire Patheon Inc. (PNHNF.PK) for US$3.55 won't cut it, leaving the latter's share price at a stand still for the time being, says Desjardins Securities analyst Maher Yaghi. Lonza submitted its proposal for Patheon on Friday only to have it...
- External links 2009-08-25
- Pharma: Dividend Payouts Shrink
- FP Trading Desk submits: With important patents set to expire and existing drug development pipelines proving disappointing, large cap U.S. pharmaceutical companies are likely to make more acquisitions down the road to shore up their vulnerable product stables. But unlike in the past, these companies will be forced...
- External links 2009-08-14
- Healthcare and Biotech Stocks Only Positives in Predominantly Negative Market
- FP Trading Desk submits: The recently completed third quarter will mark the fifth consecutive quarter of negative earnings growth for the S&P 500 index, says U.S. Sector strategist Brian Belski, with consensus expectations for year-over-year quarterly growth now at –7.4%. But even that projection is overly optimistic, he says,...
- External links 2008-10-16
- JP Morgan Analyst: Johnson & Johnson Not Worth the Sum of Its Parts
- FP Trading Desk submits: Johnson & Johnson JNJ, one of the market’s best large cap performers year-to-date, was downgraded by JP Morgan in a contrarian call as a result of its now hefty premium to the sum of its parts. The stock has fallen just 4% so far in...
- External links 2008-10-29
- Improvements at Rogers Communications Causes Shares to Rise
- FP Trading Desk submits: Rogers Communications Inc. RCI shares climbed Monday following reports that founder and CEO Ted Rogers was showing signs of recovery. The stock was up more than 2% or C$0.76 to C$35.75 just before 10 a.m. ET on the first day of trading after Mr. Rogers...
- External links 2008-11-04
- Johnson & Johnson Investors Will Feel Pain Before Gain - UBS
- FP Trading Desk submits: When it comes to Johnson & Johnson JNJ, investors will likely feel some pain, before realizing the gain, says UBS analyst Bruce Nudell. The analyst told investors in a research note: by FP Trading Desk
- External links 2009-03-22
- Pfizer: Best U.S. Large-Cap Idea for 2009 - RBC
- FP Trading Desk submits: Pfizer Inc. PFE gets the nod from the RBC Capital Markets crack team of quantitative analysts as the best US large-cap idea for 2009. The team said in a note to clients that Pfizer has a lot of things going for it right now, including...
- External links 2009-01-09
Additional Resources
- CGI Group Wins Contracts, Investor Confidence Boosted
- FP Trading Desk submits: One company that doesn't seem bothered by the recession is CGI Group Inc. GIB, who Wednesday landed their third big contract in just two weeks. Following on the heels of two contracts in the government and healthcare sectors worth approximately $310-million over five years, the...
- External links 2009-03-20
- << Previous
- page 1 of 1
- Next >>
Presented by American Express